A double-blind randomized withdrawal study evaluating the efficacy and safety of SR58611A [amibegron] versus placebo in the prevention of relapse of anxiety up to 1 year in patients with GAD [generalised anxiety disorder] improved after 12 weeks of open label treatment with SR58611A
Phase of Trial: Phase III
Latest Information Update: 24 Apr 2014
At a glance
- Drugs Amibegron (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Acronyms VEGA
- Sponsors Sanofi
- 07 Jul 2009 Actual patient number (257) added as reported by ClinicalTrials.gov.
- 25 Nov 2006 New trial record.